Antibody-drug conjugate · Cytotoxic, directed at SLITRK6 · developed by Genmab
GEN1106 is an antibody-drug conjugate whose monoclonal antibody binds SLITRK6, a leucine-rich repeat neuronal transmembrane protein overexpressed on some cancer cells. After binding and internalization, a cytotoxic agent is released to kill the SLITRK6-expressing cells. It is studied in solid tumors and urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07416123 | Phase 1 | Solid Tumors | Recruiting | GMAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid TumorsUrothelial Carcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →